Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genmab ( (GMAB) ) has shared an update.
On January 21, 2026, Genmab reported that 2025 worldwide net trade sales of the multiple myeloma therapy DARZALEX (daratumumab), including its subcutaneous formulation DARZALEX FASPRO, reached USD 14.351 billion, according to figures from license partner Johnson & Johnson’s Janssen unit. Sales totaled USD 8.266 billion in the United States and USD 6.085 billion in the rest of the world, and Genmab earns royalties on all global DARZALEX sales under its exclusive worldwide license agreement with J&J, underscoring the product’s continued commercial strength and its importance as a major revenue driver for the Danish biotech.
The most recent analyst rating on (GMAB) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody-based medicines for cancer and other serious diseases. Established in 1999 and headquartered in Copenhagen with a presence across North America, Europe and Asia Pacific, the company has built a portfolio that spans bispecific antibodies, antibody–drug conjugates, immune‑modulating antibodies and other next‑generation modalities, powering eight approved antibody medicines and a strong late‑stage clinical pipeline, including wholly owned programs.
Average Trading Volume: 1,840,551
Technical Sentiment Signal: Buy
Current Market Cap: $19.76B
See more data about GMAB stock on TipRanks’ Stock Analysis page.